# A case report of ‘Two-Hit’ digenic mutations in PAH: role of PADN in management

**Authors:** Zai-qiang Zhang, Zhou-qiang Qin, Sheng-kui Zhu, Yu-hong Zuo, Jia-wang Ding

PMC · DOI: 10.3389/fphar.2025.1601777 · 2025-07-15

## TL;DR

A 47-year-old woman with PAH caused by two rare gene mutations showed significant improvement after targeted therapy and pulmonary artery denervation.

## Contribution

This is one of the rare cases of PAH caused by digenic mutations in FLNA and MMACHC, with successful treatment using PAH-specific therapy and PADN.

## Key findings

- The patient had digenic mutations in FLNA and MMACHC, contributing to PAH.
- Symptoms improved significantly over 2 years with targeted therapy and PADN.
- The case emphasizes the value of genetic screening and personalized treatment in PAH.

## Abstract

Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary disorder characterized by progressive elevation of pulmonary vascular resistance, resulting to right ventricular dysfunction and premature mortality. Although genetic mutations are increasingly recognized in PAH pathogenesis, cases involving digenic mutations remain exceptionally rare.

We report the case of a 47-year-old female presenting with a 5-year history of exertional dyspnea, which progressively worsened over the preceding 2 months. Diagnostic imaging revealed pulmonary artery dilatation and right heart enlargement, and right heart catheterization confirmed PAH with a mean pulmonary arterial pressure of 43 mmHg. Whole exome sequencing identified a novel heterozygous mutation in FLNA (c.4754C>T, p.Thr1585Met) and a known heterozygous mutation in MMACHC (c.609G>A, p.Trp203Ter). The patient was initiated on PAH-specific therapy and pulmonary artery denervation (PADN) treatment. Over a 2-year follow-up period, her symptoms significantly improved, with no evidence of heart failure progression.

This case highlights a rare instance of PAH associated with digenic mutations in FLNA and MMACHC. The patient demonstrated a favorable response to targeted PAH therapy and PADN treatment, highlighting the importance of genetic screening and personalized treatment strategies in PAH management.

## Linked entities

- **Genes:** FLNA (filamin A) [NCBI Gene 2316], MMACHC (metabolism of cobalamin associated C) [NCBI Gene 25974]
- **Diseases:** pulmonary arterial hypertension (MONDO:0015924), PAH (MONDO:0015924)

## Full-text entities

- **Genes:** PROC (protein C, inactivator of coagulation factors Va and VIIIa) [NCBI Gene 5624] {aka APC, PC, PROC1, THPH3, THPH4}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, BMPR2 (bone morphogenetic protein receptor type 2) [NCBI Gene 659] {aka BMPR-II, BMPR3, BMR2, BRK-3, POVD1, PPH1}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, PAH (phenylalanine hydroxylase) [NCBI Gene 5053] {aka PH, PKU, PKU1}, ACVRL1 (activin A receptor like type 1) [NCBI Gene 94] {aka ACVRLK1, ALK-1, ALK1, HHT, HHT2, ORW2}, TNNI3 (troponin I3, cardiac type) [NCBI Gene 7137] {aka CMD1FF, CMD2A, CMH7, RCM1, TNNC1, cTnI}, LPA (lipoprotein(a)) [NCBI Gene 4018] {aka AK38, APOA, LP}, FLNA (filamin A) [NCBI Gene 2316] {aka ABP-280, ABPX, CSBS, CVD1, FGS2, FLN}, MMACHC (metabolism of cobalamin associated C) [NCBI Gene 25974] {aka cblC}, ENG (endoglin) [NCBI Gene 2022] {aka END, HHT1, ORW1}
- **Diseases:** rheumatic (MESH:D012216), PADN (MESH:D000071079), cardiovascular (MESH:D002318), pulmonary vascular dysfunction (MESH:D002561), arterial occlusion (MESH:D001157), neuronal migration disorders (MESH:D054081), vascular instability (MESH:D043171), pulmonary embolism (MESH:D011655), PA (MESH:C535387), intellectual disability (MESH:D008607), schizophrenia (MESH:D012559), genetic abnormality (MESH:D030342), pulmonary hypertension (MESH:D006976), death (MESH:D003643), hearing impairment (MESH:D034381), chest tightness (MESH:D002637), X-linked dominant genetic disease (MESH:D040181), right ventricular hypertrophy (MESH:D017380), hyperactive sympathetic (MESH:D006948), metabolic dysfunction (MESH:D008659), malignancy (MESH:D009369), inflammatory (MESH:D007249), cardiac and pulmonary dysfunction (MESH:D006331), right heart enlargement (MESH:D006332), edema (MESH:D004487), MMACHC gene deficiency (MESH:C567347), cardiopulmonary diseases (MESH:D006323), epilepsy (MESH:D004827), bicuspid aortic valve (MESH:D000082882), vasculitis (MESH:D014657), antiphospholipid (MESH:D016736), developmental delay (MESH:D002658), hypotonia (MESH:D009123), lung diseases (MESH:D008171), addictive drug (MESH:D019966), artery (MESH:D012078), heart failure (MESH:D006333), right ventricular dysfunction (MESH:D018497), mitochondrial dysfunction (MESH:D028361), tricuspid regurgitation (MESH:D014262), dyspnea (MESH:D004417), hypothyroidism (MESH:D007037), methylmalonic aciduria (MESH:C537358), visual impairment (MESH:D014786), patent ductus arteriosus (MESH:D004374), PAH (MESH:D000081029), periventricular nodular heterotopia (MESH:D054091)
- **Chemicals:** macitentan (MESH:C533860), tadalafil (MESH:D000068581), PAP (MESH:D010724), N-terminal pro-brain natriuretic peptide (-), oxygen (MESH:D010100)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.4754C>T, p.Thr1585Met, p.Trp203Ter, c.4754C>T, p.Thr1585Met, c.271dupA

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12303798/full.md

---
Source: https://tomesphere.com/paper/PMC12303798